110690-93-2

Upstream product

• 3874-54-2 4-(4-fluorophenyl)-4-oxo-n-butyl chloride 

Downstream Products

• 103543-82-4 (1-fluorocyclopropyl)(4-fluorophenyl)methanone 
• 1371591-93-3 (1-fluorocyclopropyl){4-[(4-methoxybenzyl)oxy]phenyl}methanone 
• 1371591-95-5 (1-fluorocyclopropyl)(4-hydroxyphenyl)methanone 
• 1371591-97-7 tert-butyl 2-fluoro-4-{5-[(1R)-1-{4-[(1-fluorocyclopropyl)carbonyl]phenoxy}propyl]-1,2,4-oxadiazol-3-yl}benzoate 
• 1371591-99-9 2-fluoro-4-{5-[(1R)-1-{4-[(1-fluorocyclopropyl)carbonyl]phenoxy}propyl]-1,2,4-oxadiazol-3-yl}benzoic acid 
• 1588767-66-1 (S)-4-chloro-2-fluoro-1-(4-fluorophenyl)-2-phenylbutan-1-one 
• 1588766-55-5 2-bromo-4-chloro-2-fluoro-1-(4-fluorophenyl)butan-1-one 

Relevant academic research and scientific papers

Catalytic asymmetric synthesis of tertiary alkyl fluorides: Negishi cross-couplings of racemic α,α-dihaloketones

The development of new approaches to the construction of fluorine-containing target molecules is important for a variety of scientific disciplines, including medicinal chemistry. In this Article, we describe a method for the catalytic enantioselective syn

ACYLBENZENE DERIVATIVE

Provided are compounds having an excellent hypoglycemic action and a β cell- or pancreas-protecting action or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause an increase in the blood sugar level due to abnormal sugar metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed.